Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Total Debt (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Total Debt for 6 consecutive years, with $48.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Debt fell 7.2% to $48.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $48.2 million, a 7.2% decrease, with the full-year FY2025 number at $48.2 million, down 7.2% from a year prior.
  • Total Debt was $48.2 million for Q4 2025 at GeneDx Holdings, down from $51.6 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $52.7 million in Q4 2023 to a low of $6.1 million in Q3 2023.
  • A 5-year average of $30.1 million and a median of $19.3 million in 2021 define the central range for Total Debt.
  • Peak YoY movement for Total Debt: crashed 53.2% in 2023, then soared 759.78% in 2024.
  • GeneDx Holdings' Total Debt stood at $13.6 million in 2021, then fell by 27.75% to $9.8 million in 2022, then soared by 435.28% to $52.7 million in 2023, then decreased by 1.47% to $51.9 million in 2024, then decreased by 7.2% to $48.2 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Total Debt are $48.2 million (Q4 2025), $51.6 million (Q3 2025), and $51.7 million (Q2 2025).